TABLE 2.
Patient or control no. | SIb for:
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
nWI-1 | rWI-1 | C-term | T-repeat | 4D | N-term | N1 | N2 | N3 | N4 | N5 | |
Patients | |||||||||||
1 | 170 | 70 | 47 | 121 | 88 | 14 | 0.3 | 0.9 | 0.3 | 0.4 | 0.5 |
11 | 15 | 6.6 | 2.5 | 5.4 | 1.0 | 3.3 | 1.4 | 2.2 | 6.6 | 0.6 | 1.4 |
18 | 110 | 80 | 64 | 86 | 75 | 13 | 0.3 | 0.9 | 0.2 | 0.2 | 0.3 |
20 | 44 | 35 | 24 | 21 | 19 | 20 | 0.8 | 0.5 | 4.7 | 0.3 | 0.2 |
29 | 270 | 110 | 82 | 190 | 96 | 39 | 0.1 | 1.0 | 0.1 | 0.1 | 0.3 |
32 | 48 | 22 | 15 | 24 | 15 | 19 | 0.5 | 1.1 | 6.3 | 0.9 | 0.5 |
Controlsc | |||||||||||
1 | 2.2 | 2.5 | 1.1 | 0.8 | 2.9 | 0.7 | 0.8 | 1.2 | 0.7 | 0.8 | 0.7 |
2 | 0.1 | 0.5 | 0.3 | 1.2 | 1.7 | 0.4 | 0.6 | 1.0 | 1.4 | 0.6 | 1.0 |
WI-1, native WI-1; C-term, C terminus; T-repeat, tandem repeat; N-term, N terminus.
An SI of 3 or greater is considered positive.
PBMCs from control subjects responded to positive control stimuli of conA (SI = 24 and 38) and IL-2 (SI = 77 and 130).